New screening tool IDs 95% of stage 1 pancreatic cancer

A novel screening platform has flagged more than 95% of stage 1 cancers, according to a pilot study published in Nature Communications Medicine. If validated by future studies, the approach offers a new way to detect the third-leading cause of U.S. cancer deaths in 2020.
A novel screening platform has flagged more than 95% of stage 1 cancers, according to a pilot study published in Nature Communications Medicine. If validated by future studies, the approach offers a new way to detect the third-leading cause of U.S. cancer deaths in 2020.